Safety, immunogenicity and immediate pain of intramuscular versus subcutaneous administration of a measles-mumps-rubella-varicella vaccine to children aged 11-21 months

European Journal of Pediatrics

Volumn 169, Issue 8, 2010, Pages 925-933

  Knuf, Markus ^a,b   Zepp, Fred ^b   Meyer, Claudius U ^b   Habermehl, Pirmin ^c   Maurer, Lothar ^d   Burow, Hanns Michael ^c   Behre, Ulrich ^e   Janssens, Michel ^f   Willems, Paul ^f   Bisanz, Helmtrud ^g   Vetter, Volker ^g   Schmidt Ott, Ruprecht ^g  

^a DR HORST SCHMIDT KLINIKEN   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c Pediatric Office   (Germany)

^d Pediatric Office   (Germany)

^e Pediatric Office   (Germany)

^f GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^g GLAXOSMITHKLINE   (Germany)

Author keywords

Cell mediated immunity; Immunogenicity; Intramuscular; Measles mumps rubella varicella vaccine; Safety; Subcutaneous

Indexed keywords

CHICKENPOX MEASLES MUMPS RUBELLA VACCINE; PRIORIX TETRA; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CHICKENPOX; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE RASH; INJECTION SITE SWELLING; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MEASLES; MULTICENTER STUDY; MUMPS; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RUBELLA; SEROCONVERSION;

ANTIBODIES, VIRAL; ANTIBODY FORMATION; CHICKENPOX VACCINE; EXANTHEMA; FEMALE; FEVER; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNITY, HUMORAL; INFANT; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; MALE; MEASLES-MUMPS-RUBELLA VACCINE; PAIN;

EID: 77954426654     PISSN: 03406199     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00431-010-1142-6     Document Type: Article

References (38)

1. K Banz S Wagenpfeil A Neiss, et al. 2004 The burden of varicella in Germany. Potential risks and economic impact Eur J Health Econ 5 46 53 10.1007/s10198-003-0200-7 15452764 (Pubitemid 38315897)
2. PY Boelle T Hanslik 2002 Varicella in non-immune persons: incidence, hospitalization and mortality rates Epidemiol Infect 129 599 606 10.1017/S0950268802007720 1:STN:280:DC%2BD3s%2FkvVKmug%3D%3D 12558344
3. J Bonhoeffer G Baer B Muehleisen, et al. 2005 Prospective surveillance of hospitalisations associated with varicella-zoster virus infections in children and adolescents Eur J Pediatr 164 366 370 10.1007/s00431-005-1637-8 15747132 (Pubitemid 40869010)
4. JC Cameron G Allan F Johnston, et al. 2007 Severe complications of chickenpox in hospitalised children in the UK and Ireland Arch Dis Child 92 1062 1066 10.1136/adc.2007.123232 1:STN:280:DC%2BD2snpsFaqsw%3D%3D 17991685 (Pubitemid 350221447)
5. Centers for Disease Control and Prevention (2007) Epidemiology and prevention of vaccine-preventable diseases. In: Atkinson W, Hamborsky J, McIntyre L, Wolfe S (eds) The Pink book, 10th edn. Public Health Foundation, Washington, DC
6. C Clements M Strassburg FT Cutts, et al. 1992 The epidemiology of measles World Health Stat Q 45 285 291 1:STN:280:DyaK3s%2FpslOltg%3D%3D 1462663
7. Committee for Medicinal products for Human use (CHMP) (2006) European Public Assessment Report on MMRV. http://www.emea.europa.eu/humandocs/PDFs/EPAR/ proquad/062206en6.pdf
8. HA Gans LL Yasukawa CZ Zhang, et al. 2008 Effects of interleukin-12 and interleukin-15 on measles-specific T-cell responses in vaccinated infants Viral Immunol 21 2 163 172 10.1089/vim.2007.0113 1:CAS:528:DC%2BD1cXnsVCms74%3D 18419254 (Pubitemid 351873373)
9. A Gil M San-Martin P Carrasco, et al. 2004 Epidemiology of severe varicella-zoster virus infection in Spain Vaccine 22 3947 3951 10.1016/j.vaccine.2004.04.004 15364443 (Pubitemid 39208757)
10. Y Gillet P Habermehl S Thomas, et al. 2009 Immunogenicity and safety of concomitant administration of a measles, mumps and rubella vaccine (M-M-RvaxPro) and a varicella vaccine (VARIVAX) by intramuscular or subcutaneous routes at separate injection sites: a randomised clinical trial BMC Med 7 16 10.1186/1741-7015-7-16 19366435
11. P Goh FS Lim HH Han, et al. 2007 Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age Infection 35 326 333 10.1007/s15010-007-6337-z 1:CAS:528:DC%2BD2sXht1emu7fJ 17710370 (Pubitemid 47502355)
12. V Grote R von Kries W Springer, et al. 2008 Varicella-related deaths in children and adolescents-Germany 2003-2004 Acta Ped 97 187 192 10.1111/j.1651-2227.2007.00595.x (Pubitemid 351197949)
13. JM Guillen M de la Luz Samaniego-Colmenero V Hernandez-Barrera, et al. 2008 Varicella paediatric hospitalizations in Spain Epidemiol Infect 137 519 525 10.1017/S0950268808001131 18667111
14. R Hanna-Wakim LL Yasukawa P Sung, et al. 2008 Immune responses to mumps vaccine in adults who were vaccinated in childhood J Infect Dis 197 12 1669 1675 10.1086/588195 1:CAS:528:DC%2BD1cXotFagsLs%3D 18419345 (Pubitemid 351919630)
15. M Ipp E Cohen M Goldbach, et al. 2004 Effect of choice of measles-mumps-rubella vaccine on immediate vaccination pain in infants Arch Pediatr Adolesc Med 158 323 326 10.1001/archpedi.158.4.323 15066870 (Pubitemid 38451557)
16. M Ipp E Cohen M Goldbach, et al. 2006 Pain response to M-M-R vaccination in 4-6 year old children Can J Clin Pharmacol 13 3 e296 e299 17127775
17. M Ipp PC Parkin N Lear, et al. 2009 Order of vaccine injection and infant pain response Arch Pediatr Adolesc Med 163 5 469 472 10.1001/archpediatrics. 2009.35 19414694
18. M Knuf P Habermehl F Zepp, et al. 2006 Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children Pediatr Infect Dis J 25 12 18 10.1097/01.inf.0000195626.35239.58 16395096 (Pubitemid 43361469)
19. BJ Kuter ML Brown J Hartzel, et al. 2006 Safety and immunogenicity of a combination measles, mumps, rubella and varicella vaccine (ProQuad) Hum Vaccin 2 205 214 1:CAS:528:DC%2BD28XhtlWlurvL 17035730
20. A Lanzavecchia F Sallusto 2002 Progressive differentiation and selection of the fittest in the immune response Nat Rev Immunol 2 12 982 987 10.1038/nri959 1:CAS:528:DC%2BD38XptFKmsr8%3D 12461571 (Pubitemid 37323221)
21. SM Marcy 2003 Pediatric combination vaccines: their impact on patients, providers, managed care organizations, and manufacturers Am J Manag Care 9 314 320 12703675
22. M Marin D Guris SS Chaves, et al. 2007 Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Recomm Rep 56 1 40 17585291
23. PA Meyer JF Seward AO Jumaan, et al. 2000 Varicella mortality: trends before vaccine licensure in the United States, 1970-1994 J Infect Dis 182 383 390 10.1086/315714 1:STN:280:DC%2BD3cvlvFSjug%3D%3D 10915066 (Pubitemid 30654820)
24. AL Ngai BO Staehle BJ Kuter, et al. 1996 Safety and immunogenicity of one vs. two injections of Oka/Merck varicella vaccine in healthy children Pediatr Infect Dis J 15 49 54 10.1097/00006454-199601000-00011 1:STN:280: DyaK283nsVaksQ%3D%3D 8684876 (Pubitemid 26029243)
25. T Nolan P McIntyre D Roberton, et al. 2002 Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine Vaccine 21 281 289 10.1016/S0264-410X(02)00459-0 1:CAS:528:DC%2BD38XovFGnur8%3D 12450703 (Pubitemid 35346822)
26. H Petousis-Harris 2008 Vaccine injection technique and reactogenicity-evidence for practice Vaccine 26 6299 6304 10.1016/j.vaccine. 2008.08.052 18804137
27. KS Reisinger ML Hoffman Brown, et al. 2006 A combination measles, mumps, rubella and varicella vaccine (ProQuad) given to 4- to 6- year-old healthy children vaccinated previously with M-M-RII and Varivax Pediatrics 117 265 272 10.1542/peds.2005-0092 16452343
28. B Rentier AA Gershon The members of EuroVar the European Working Group on Varicella (EuroVar) 2004 A consensus paper: varicella vaccination of healthy children-a challenge for Europe Pediatr Infect Dis J 23 379 389 10.1097/01.inf.0000122606.88429.8f 15131459 (Pubitemid 38621475)
29. Robert Koch-Institut 2006 Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: Juli 2006 Epidemiol Bulletin 30 235 254
30. V Schuster W Otto L Maurer, et al. 2008 Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life Pediatr Infect Dis J 27 724 730 10.1097/INF.0b013e318170bb22 18600190
31. MA Suni LJ Picker VC Maino 1998 Detection of antigen-specific T cell cytokine expression in whole blood by flow cytometry J Immunol Methods 212 1 89 98 10.1016/S0022-1759(98)00004-0 1:CAS:528:DyaK1cXjtVKlsbs%3D 9671156 (Pubitemid 28288190)
32. T Vesikari M Baer P Willems 2007 Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years Pediatr Infect Dis J 26 153 158 10.1097/01.inf.0000250689.09396.21 17259879 (Pubitemid 46183366)
33. T Vesikari C Sadzot-Delvaux B Rentier, et al. 2007 Increasing coverage and efficiency of measles, mumps, and rubella vaccine and introducing universal varicella vaccination in Europe: a role for the combined vaccine Pediatr Infect Dis J 26 632 638 10.1097/INF.0b013e3180616c8f 17596807 (Pubitemid 47014166)
34. World Health Organization Europe 2002 Measles surveillance in the European region EURO Measles Q 2003 Issue 2 1 4
35. World Health Organization 2004 Measles vaccines Wkly Epidemiol Rec 79 130 142
36. World Health Organization 2007 Mumps virus vaccines Wkly Epidemiol Rec 82 51 60
37. F Zepp U Behre K Kindler, et al. 2007 Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine co-administered with a booster dose of a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in healthy children aged 12-23 months Eur J Pediatr 166 857 864 10.1007/s00431-007-0506-z 17541639 (Pubitemid 46988187)
38. Zepp F, Manegold-Randel D, Helm K, et al (2008) Antibody persistence and varicella breakthrough case assessment three years after administration of measles-mumps-rubella-varicella (MMRV) vaccine in children aged 11-23 months [abstract]. Program and abstracts of the 26th Annual Meeting of the European Society of Paediatric Infectious Diseases (Graz, Austria)